ACTR-76. FINAL RESULTS FROM A PHASE I STUDY OF PLERIXAFOR AND BEVACIZUMAB IN RECURRENT HIGH-GRADE GLIOMA

Although anti‐angiogenic therapy for high-grade glioma (HGG) is promising, responses are not durable. The SDF-1/CXCR4 axis may help mediate resistance to VEGFR inhibition. Plerixafor is a reversible CXCR4 inhibitor that has demonstrated growth inhibition in glioblastoma xenografts. We conducted a Ph...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Neuro Oncol
Main Authors: Lee, Eudocia, Muzikansky, Alona, Gerstner, Elizabeth, Kuhn, John, Reardon, David, Nayak, Lakshmi, Norden, Andrew, Doherty, Lisa, Stefanik, Jennifer, Armitage, Julee, LaFrankie, Debra, Ruland, Sandra, Vardam, Trupti, Stokes, Deirdre, Smith, Katrina, McCluskey, Christine, Gaffey, Sarah, Batchelor, Tracy, Jain, Rakesh, Duda, Dan, Wen, Patrick
פורמט: Artigo
שפה:Inglês
יצא לאור: Oxford University Press 2017
נושאים:
Abstracts
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692502/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.063
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים